On April 27, 2023 Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported that it will be presenting at the 20th Association for Cancer Immunotherapy (CIMT) (Free CIMT Whitepaper) annual meeting being held on May 3-5, 2023, in Mainz (Press release, MediGene, APR 27, 2023, View Source [SID1234630629]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data to be presented will focus on Expitope 3.0, an in silico tool to identify immunogenic epitopes as suitable T cell receptor (TCR) target specificities. Moreover, Expitope 3.0, enables the comparison of expression of epitopes in various healthy tissues to predict potential cross-reactivity and off-target toxicity. Presentation of the data includes a poster as well as an oral presentation.
The abstract has been published online: View Source
Details on the poster presentation are as follows:
Abstract and Title: "Expitope 3.0 – An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLA Epitope Prediction and Safety Assessment"
Authors: Sebastian Karg, Andrea Coluccio, Barbara Lösch, Dolores J Schendel, Dimitri Frishmann
Abstract Number: 98
Date/Time: Wednesday, May 3rd, 2023, 3:00 pm – 5.30 pm CET
Session: Postersession I
Details on the oral presentation are as follows:
Abstract and Title: "Expitope 3.0 – An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLA Epitope Prediction and Safety Assessment"
Speaker: Dr. Barbara Lösch
Date/Time: Thursday, May 4th, 2023, 11.00 am – 11.15 am CET